Rezulin Articles
US Suprme Court deadlock on drug case
10 March 2008
UPDATE: US Supreme Court in deadlock over drug case
10 March 2008
SCOTUS signals FDA pre-emption support
3 March 2008
US Supreme Court to review FDA pre-emption
8 October 2007
Japan stock market week to Sept 4, 2006
11 September 2006
Generics battering Sankyo's home sales
4 October 2004
Pfizer settles Rezulin law suit
12 July 2004
Pfizer seeks to set aside a New York Rezulin verdict
14 April 2003
Sankyo to help GSK sell Avandia in Japan
3 February 2003
Pfizer settles Rezulin case
7 January 2002
Pfizer settles Rezulin case
24 December 2001
Rezulin class-action certification denied
10 December 2001
GlaxoSmithKline warned over Avandia promotion by US FDA
6 August 2001
Pfizer 1st-qtr 2001 net income rises 34%
23 April 2001
Pfizer forecasts strong revenue growth in 2001-2002 at R&D meeting
14 December 2000
Good prospects for Ono's Elaspol; HSBC
22 August 2000
Sankyo seeks FDA OK for hypertension drug
1 August 2000
Sankyo looks to new drug to boost US presence
6 July 2000
Stock Commentary Europe
25 May 2000
Takeda benefits from strong US showing
24 May 2000
Stock Commentary Tokyo
27 April 2000
SB tops UK corporate reputation list in March
25 April 2000
Actos takes the lead in new prescriptions
13 April 2000
Stock Commentary Tokyo
6 April 2000
Stock Commentary New York
6 April 2000
Stock Commentary Tokyo
3 April 2000
Class action against W-L over Rezulin
31 March 2000
Concern over warning labels' effectiveness
27 March 2000
SB wins Avandia approval in Europe, but use restricted
17 March 2000
Stock Commentary Tokyo
24 February 2000
Avandia implicated again in hepatic injury, SB denies link
19 January 2000
SB's Avandia "leading the class" in the USA
13 January 2000
Busy year for NCEs as major new compound classes launched
6 January 2000
Stock Commentary Tokyo
2 December 1999
Takeda to launch Actos in Japan; $1bn drug?
2 December 1999
Sankyo turnover falls
15 November 1999
Stock Commentary Tokyo
11 November 1999
Avandia CPMP knockback overshadows SB's promising growth
25 October 1999
"Rising tide" of pharma consolidation reviewed by banker
21 October 1999
SB rebuffs suggestion of Avandia toxicity
11 October 1999
Stock Commentary New York
9 September 1999
SB denies Avandia liver damage rumors
2 September 1999
Stock Commentary Tokyo
29 July 1999
Actos approval shortly?
16 July 1999
Sankyo and W-L in promotion campaign for Rezulin
6 July 1999
Novo Nordisk's Prandin plus Rezulin, insulin
24 June 1999
Stock Commentary Tokyo
27 May 1999
Strong net profits growth for Sankyo
24 May 1999
Stock Commentary Tokyo
29 April 1999
SB boosted as Avandia is backed by FDA advisory panel
23 April 1999
W-L accused of cooking Rezulin results
7 April 1999
Stock Commentary Tokyo
31 March 1999
Stock Commentary New York
31 March 1999
Troglitazone shows promise in cancer
30 March 1999
Stock Commentary Europe
29 March 1999
Stock Commentary Tokyo
29 March 1999
Stock Commentary New York
29 March 1999
Analysts discuss impact of troglitazone meeting
29 March 1999
MCA rejects reintroduction of troglitazone in the UK
23 March 1999
Priority review for Takeda's Actos in USA
18 March 1999
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
